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APPA PROVIDES SYMPTOM RELIEF IN CLINICAL CANINE
OSTEOARTHRITIS
S. Glasson 1, N. Larkins 2. 1ALK Intl., Cook, Australia; 2ALK Intl., Barcelona,
Spain
Purpose: Lameness due to osteoarthritis (OA) is common in aged dogs and
altered weight bearing can be objectively quantiﬁed. Oral APPA (apocynin
and paeonol), and underwater treadmill therapy (UTW) were evaluated in
client-owned dogs with OA, for normalization of weight bearing utilizing
force-plate measurements, pre and post 4 weeks of treatment.
Methods: OA was diagnosed in client-owned dogs by physical examina-
tion and conﬁrmed by radiography. Thirty-two dogs were enrolled with
half having elbow and half hip OA. Treatment consisted of either 50 mg/kg
BID oral APPA or twice weekly sessions of underwater treadmill (UWT)
therapy for 4 weeks with all dogs receiving both treatments, with a wash-
out period of 3 weeks in-between. Half the animals received APPA ﬁrst,
and half the animals received UWT ﬁrst. Force plate measures were
obtained before and after each treatment at a consistent treadmill speed
for each dog (average of 0.6 + 0.09 m/s). No other pain medications,
including nutraceuticals, were administered to any of the dogs for the
duration of the study. Ground reaction force (GRF) measures from 5 strides
were used to calculate peak vertical force (PFz), mean vertical force (MFz),
and vertical impulse (IFz). Symmetry indices (SI) for the limb pairs (left and
right forelimbs for dogs with elbow OA, left and right hindlimbs for dogs
with hip OA) were calculated for each of the three measurements, with
a high SI indicating more asymmetry (or lameness), and absolute
symmetry giving a SI of zero. Individual dog pre- and post-treatment SI
values were compared with Wilcoxon matched pairs non-parametric test.
Results: The dogs enrolled in the study were middle to older-aged and
mid-large sized (6 + 4 years and 30 + 9 kg). Two dogs in the initial UWT
group were withdrawn from the study, with one requiring NSAID therapy
for pain, and the other had a cardiac tumor. The UWT was well tolerated
and the duration of each twice-weekly session steadily increased from 5 +
2 min to 21 + 7 min over the 4 week treatment period. Twice daily oral
APPAwas well tolerated for 4 weeks in all but one of the 32 dogs who was
removed from the study following mild gastrointestinal signs (vomiting
following dosing). A total of 29 dogs completed the study and received the
two, 4-week treatments, with a total study length of 11 weeks (including
the 3weekwash-out interval). APPA decreased Peak Vertical Force SI when
compared to pre-treatment levels (p < 0.02, Wilcoxon test), decreased
Mean Vertical Force SI (p¼ 0.0001), and decreased Vertical Impulse SI (p<
0.0001). Gait symmetry indices following both APPA and UWTapproached
those obtained historically from healthy dogs.
Conclusions: APPA and UWT therapy were well-tolerated in client-owned
dogs and normalized gait asymmetry, as measured with an objective force
plate system. APPA normalized gait symmetry indices without the need for
UWT equipment or specialized supervision. APPA has also demonstrated
decreased disease progression in a rat meniscal tear model of OA, but
disease progression was not examined in this dog study. APPA is being
further investigated for its ability to decrease pain, clinically in human and
veterinary patients, and to decrease cartilage destruction in preclinical
models.
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A RANDOMIZED CONTROLLED STUDY FOR THE COMPARISON OF
EFFICACY AND SAFETY ASSESSMENT OF INTRA-ARTICULAR INJECTION
OF HIGH MOLECULAR WEIGHT HYALURONIC ACID AND ORAL NON-
STEROIDAL ANTI-INFLAMMATORY DRUGS FOR JAPANESE PATIENTS
WITH KNEE OSTEOARTHRITIS (UMIN000001026)
M. Ishijima 1, T. Nakamura 2, K. Shimizu 3, K. Hayashi 4, K. Kaneko 1. For
Research Group of Cartilage Metabolism1 Juntendo Univ. Graduate Sch. of
Med., Tokyo, Japan; 2Univ. of Occupational and Environmental Hlth.,
Fukuoka, Japan; 3Gifu Univ., Sch. of Med., Gifu, Japan; 4Gunma Univ.,
Gunma, Japan
Purpose: Among the pharmacological treatment for knee osteoarthritis
(OA), oral non-steroidal anti-inﬂammatory drugs (NSAIDs) are recom-
mended to be used in OARSI recommendations for the management of OA.Although intra-articular injections of hyaluronic acid (IA-HA) are also
recommended, there was very considerable heterogeneity of outcomes
between trials. IA-HA is more common in clinical medicine in Japan.
However, there is no direct comparison in terms of the efﬁcacy and safety
of these two treatments in Japanese patients with knee OA. The aim of this
multicenter randomized controlled head-to-head comparison study was
to clarify that IA-HA was not inferior to NSAID for the treatment of Japa-
nese patients with knee OA.
Methods: A total of 200 patients with knee OA (K/L grade 1 to 3) were
registered from nineteen hospitals and randomized to NSAID (loxoprofen
sodium, Loxonin) or IA-HA (High molecular weight 2,700 kDa HA,
Suvenyl). For patients treated with NSAID, they used NSAID 3 tablets (180
mg)/day for ﬁve weeks. For patients treated with IA-HA, intra-articular
injection of high molecular weight HAwas conducted for 5 times with one
week interval. The trial was conducted in accordance with the Declaration
of Helsinki. All patients provided written informed consent before
enrollment in this trial. The protocol was reviewed by the institutional
review board of each institution. The primary endpoint was the percent
changes of Japanese Knee Osteoarthritis Measure (JKOM), which is
a patient-oriented outcome measure for Japanese patients with knee OA,
during 5 weeks observation. The secondary endpoint was the percent
differences of pain visual analogue scale (VAS) score. The authors analyzed
the full analysis set (FAS) as the primary analysis, based on the concept of
intention-to-treat (ITT) and the per protocol set (PPS) as the secondary
analysis. As the results obtained by FAS were similar to those by PPS
analysis, data obtained from FAS analysis will be presented.
Results: During the 5 weeks of examination, while 20.4% of patients with
NSAID were withdrawn, 9.2% of patients with IA-HA were withdrawn.
These differences for the frequency of withdrawal between NSAID and IA-
HA were statistically signiﬁcant (p¼0.02). The frequency for adverse
events in patients with NSAID and IA-HA was 10.8% and 1.0%, respectively.
These differences for the frequency of adverse events between NSAID and
IA-HA were statistically signiﬁcant (p¼0.003). No signiﬁcant changes of
JKOM sc ore were observed in patients with either NSAID or IA-HA by the
treatment (p¼0.18 and 0.55, respectively). The difference of percent
changes of JKOM score between the two intervention arms (primary
outcome measure) was -1.34% (90%CI; -7.68 to 5.01), and IA-HA was non-
inferior
to NSAID. Pain VAS scores of the patients with NSAID (56.1) and IA-HA
(58.9) at baseline were signiﬁcantly reduced in comparison to those after
the treatment (31.0 and 30.3) (p<0.001), respectively. The differences of
the secondary outcome measure (% change of pain VAS score) between
two intervention arms was -5.74% (90%CI; -23.6 to 12.1), and IA-HA was
non-inferior to NSAID for pain. In addition, when the patients were divided
into two groups (responder or non-responder) by OMERACT-OARSI
response criteria, 51.5% of the patients with IA-HA were classiﬁed into
“responder”, while 49.5% of those with NSAID were “responder”. Again,
there were no signiﬁcant differences of the frequency of “responder”
between these two groups. Logistic regression analysis for odds of
responders also revealed that the patients with IA-HA were not inferior to
those with NSAID (OR 1.00 (95%CI; 0.56-1.78, p¼0.99)).
Conclusions: This study showed that the efﬁcacy of IA-HAwas not inferior
in comparison to that of NSAID, and the safety of IA-HA was superior in
comparison to that of NSAID for Japanese patients with knee OA.
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EXPLORATORY ANALYSIS OF OSTEOARTHRITIS PROGRESSION AMONG
MEDICATION USERS: DATA FROM THE OSTEOARTHRITIS INITIATIVE
J.B. Driban 1, G.H. Lo 2, C.B. Eaton 3, K.L. Lapane 4, M. Nevitt 5,
W.F. Harvey 1, T.E. McAlindon 1. 1 Tufts Med. Ctr., Boston, MA, USA; 2Michael
E. DeBakey VA Med. Ctr., Baylor Coll. of Med., Houston, TX, USA; 3Ctr. for
Primary Care and Prevention, Alpert Med. Sch. of Brown Univ., Pawtucket,
RI, USA; 4Dept. of Epidemiology and Community Hlth., Virginia
Commonwealth Univ., Richmond, VA, USA; 5Dept. of Epidemiology and
Biostatistics at the Univ. of California, San Francisco, San Francisco, CA, USA
Purpose: There has been limited success exploring disease modifying
interventions for knee osteoarthritis (OA) and it would be cost prohibitive
to explore a large number of pharmacological interventions in randomized
clinical trials. Therefore, we conducted an exploratory analysis of OA
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to identify interventions or pathways that may be of interest for future
clinical trials.
Methods: An exploratory analysis was conducted using OAI participants
with annual medication inventory form data between baseline and the 36-
month (mo) follow-up visit (n ¼ 2,938). Consistent medication users were
deﬁned for each medication classiﬁcation (class) as a participant reporting
at every annual visit that they were regularly using an oral prescription
medication at the time of the clinic visit. Two deﬁnitions of consistent
medication nonuserwere assessed: 1) deﬁnite nonuser: participants never
reported the prescription medication, and 2) probable nonuser: partici-
pants never reported regularly using an oral prescriptionmedication at the
time of the clinic visit. The exploratory analysis focused on medication
classes with  40 users. Key outcome measures were 12-mo quantitative
joint space width at x ¼ 0.250 (JSW250), JSW250 change (12-mo to 36-mo
visits), 12-mo WOMAC pain score, and WOMAC pain score change (12-mo
to 36-mo visits). Change was calculated as follow-up minus baseline. Each
medication class was analyzed separately. We explored ﬁve sets of
comparisons including threewith nonusers matched to users based on OAI
cohort, race, gender, age ( 5 years), and body mass index ( 5 kg/m2): 1)
no matching: users to all deﬁnite nonusers, 2) matched: users to deﬁnite
nonusers, 3) matched and restricted to only participants with JSW250
data: users to deﬁnite nonusers, 4) no matching: users to all probable
nonusers, and 5) matched: users to probable nonusers. A Cohen effect size
was generated for each medication class in each set of comparisons (d¼
[user mean-nonuser mean] divided by pooled standard deviation).
Medication classes with 4 out of 5 effect sizes for JSW250 change > 0.10 or
< -0.10 for WOMAC pain change were further explored with box plots to
determine if the median change of matched deﬁnite nonusers was beyond
interquartile range (IQR) of users.
Results: Twenty-six medication classes were eligible for screening (Table
1). Table 1 contains sample sizes and effect sizes for each medication class.
Anti-estrogen, anticonvulsants, antineoplastic agents, progestogens, anti-
depressants, hypoglycemics, and ACE inhibitors were further explored
with box plots for JSW250 change. Anti-estrogen users’ IQR included less
JSW250 change than the median for nonusers. Progestogens also had
a potential signal but the other medications had clear overlap between
users and nonusers. For symptommodiﬁcation, alpha-adrenergic blockers
and diuretics were further explored with box plots of WOMAC pain
change. Alpha-adrenergic users’ IQR included greater improvement in
WOMAC pain scores than the median for nonusers but diuretic users and
nonusers had clear overlap.
Conclusions: A hormonal pathway, theoretically associated with bone
turnover, may be an area for further focus since anti-estrogen and
progestogen users had evidence of slower JSW change while bisphosph-
onate users had greater JSW change. Furthermore, weak but consistent
evidence suggested that central nervous system agents may deserve
further research since anticonvulsants and antidepressant users had
slower JSW changewhile anxiolytics users had greater JSW change. Alpha-
adrenergic users had signal for improved symptoms but no other medi-
cations had complimentary signals.
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LONGITUDINAL EVALUATION OF VISCOSUPPLEMENTATION THERAPY
ON OA PATIENTS USING T1(RHO) MRI
M. Fenty 1, R. Shah 2, Y. Kuang 3, J. Stambough 4, J. Kneeland 5,
J.D. Kelly, IV 4, R. Reddy 1, F. Tjoumakaris 6. 1CMROI, Univ. of Pennsylvania,
Philadelphia, PA, USA; 2Orthopedic Surgery, Hosp. of the Univ. of
Pennsylvania, Philadelphia, PA, USA; 3 Sch. of Engineering and Applied Sci.,
Univ. of Pennsylvania, Philadelphia, PA, USA; 4 Sports Med., Hosp. of the
Univ. of Pennsylvania, Philadelphia, PA, USA; 5Radiology, Pennsylvania
Hosp., Philadelphia, Philadelphia, PA, USA; 6 The Rothman Inst., Egg Harbor
Township, NJ, Egg Harbor Township, NJ, USA
Purpose: To quantify changes to articular cartilage in patients following
viscosupplementation therapy with mild to moderate osteoarthritis using
T1r MRI.
Methods: Following IRB guidelines, 10 subjects (mean age, 56  10 yrs)
with Kellgren-Lawrence Grades 1 and 2 OA, and who never had prior VS or
knee surgery, were scanned at baseline, 6 weeks post-, and 3 months post-
VS using Hylan G-F 20 (3T, Siemens Medical Solutions, Malvern, PA). T1-
weighted isotropic MPRAGE images were acquired for segmentation of
cartilage, and T1r-weighted 3D TrueFISP imageswere acquired to calculate
spatial T1r relaxation maps. Sixteen T1r-weighted slices were acquired in
each aspect to allow for volumetric analysis. Image acquisition parameters
have been described previously. Isotropic sagittal MPRAGE images were
re-sliced along coronal and axial views and interpolated to match the
resolution of T1r- weighted images. Inter- and intra-scan motion was
corrected 3D rigid-body co-registration algorithms (Analyze, AnalyzeDir-
ect, Inc., KS). Femoral and tibial images were co-registered separately due
to discrepancies in ﬂexion angle between imaging sessions. ROI analysis
was performed on the same locations for three time points to accurately
quantify changes in T1r through mean compartmental analysis and
percent change maps from baseline images. Cartilage was segmented
using the SliceOMatic (Tomovision, Quebec, CA) software package. Co-
registered T1r-weighted images were ﬁt pixelwise to the linearized,
mono-exponential signal decay equation ln(S) ¼ -TSL/T1r + ln(S0). Volu-
metric T1r means were calculated by layer depth (superﬁcial, middle,
deep) as well as by region (medial and lateral patella, femoral condyles,
and tibial plateau). Statistical analysis was performed using a one-tailed
paired t-test between time points. Additional data to be analyzed but not
present for this abstract include the visual analog pain, WOMAC, and IKDC
subjective scores before injection and at the time of follow-up MRI.
WORMS scoring for each patient is currently being performed and will be
correlated to quantitative ﬁndings. Statistical signiﬁcance was accepted
when p<0.05.
There were signiﬁcant differences in volumetric T1r scores in both the
medial and lateral compartments of the superﬁcial patella (p< 0.05) 6
weeks following but not after three months (Med. - p<0.1, Lat. - p 20%
across the entire patella while Figure 2 has no signiﬁcant difference in
average between two following time points. There is a large region across
the middle of the lateral facet with an average T1r score < 20% versus the
volumetric mean. This trend of non-uniform spatial changes to T1r
following VS regiments is prevalent among all patients.
Conclusions: These data suggest that VS has a quantiﬁable physiolog-
ical effect on knee articular cartilage. This effect is greater in the
superﬁcial layers than in the deep layers. Intuitively, direct contact
between VS and cartilage occurs at the superﬁcial layer, and there may
be a subsequent physical mechanism of action for VS. Interestingly, the
greatest effects were observed in the patella-femoral compartment
which may be due to lower load-bearing activities and increased
cartilage thickness. Future work will assess methods to predict homo-
or heterogeneous changes within the articular cartilage through
correlation analysis with WORMS, WOMAC, and other qualitative
assessments. While some patients responded positively to the VS, as
calculated through lower T1r scores, there were some who did not or
had higher T1r values. There may be both placebo effects as well as
anti-inﬂammatory mechanisms associated with the VS which allowed
patients to push through pain more than before thereby causing
increased damage to the cartilage tissue.
